Bli medlem
Bli medlem

Du är här

2016-11-21

Xvivo Perfusion: XVIVO Perfusion has been approved for listing on Nasdaq Stockholm and publishes prospectus

Nasdaq Stockholm's listing committee has approved XVIVO Perfusion AB
("XVIVO Perfusion") for listing on the main market subject to
customary conditions.

The first day of trading in XVIVO Perfusion's shares on Nasdaq
Stockholm is planned to be on Monday, 28 November 2016. Due to the
listing on the main market, XVIVO Perfusion will be delisted from
Nasdaq First North Premier. The last day of trading on Nasdaq First
North Premier is planned to be on Friday, 25 November 2016.

XVIVO Perfusion's shares will be traded under the same ticker symbol
as before, i.e. "XVIVO". The share will also remain the same ISIN
code as used before, i.e. SE0004840718. No new shares are issued in
connection with the listing and shareholders in XVIVO Perfusion do
not need to take any action in connection hereto.

For further information, please refer to the prospectus (in Swedish)
prepared in connection with the listing on the main market which has
been approved by the Swedish Financial Supervisory Authority. The
prospectus is available, inter alia, on XVIVO Perfusion's website
www.xvivoperfusion.com/corporate.

Gernandt & Danielsson is acting as legal advisor in connection with
the listing.

November 21, 2016
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, +46 31 788 2150,
magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion's business, please refer to
the company's website, www.xvivoperfusion.com

The information in this press release was submitted for publication,
through the agency of the contact person set out above, at 5:00 p.m.
CET on November 21, 2016.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in Lund, Sweden and one office in Denver, the USA. The XVIVO share is
listed on NASDAQ First North premier and has the ticker symbol XVIVO.
More information can be found on the website www.xvivoperfusion.com.
The Certified Adviser is Redeye, www.redeye.se.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
-----------------------------------------------------------
http://news.cision.com/xvivo-perfusion/r/xvivo-perfusion-has-been-approv...
http://mb.cision.com/Main/4567/2126648/593269.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.